Fractyl Health (NASDAQ:GUTS) Shares Down 1.1%

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) fell 1.1% during trading on Thursday . The company traded as low as $6.51 and last traded at $6.57. 69,309 shares were traded during trading, a decline of 82% from the average session volume of 383,212 shares. The stock had previously closed at $6.64.

Wall Street Analyst Weigh In

GUTS has been the topic of several recent analyst reports. Evercore ISI started coverage on shares of Fractyl Health in a report on Wednesday, February 28th. They issued an “outperform” rating on the stock. Morgan Stanley began coverage on Fractyl Health in a report on Tuesday, February 27th. They issued an “overweight” rating and a $18.00 price objective on the stock. Finally, Bank of America started coverage on Fractyl Health in a research note on Tuesday, February 27th. They set a “buy” rating and a $26.00 target price for the company.

Fractyl Health Stock Performance

The stock’s 50-day moving average price is $7.74.

Insider Activity

In related news, Director Ajay Royan acquired 333,333 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was purchased at an average price of $15.00 per share, with a total value of $4,999,995.00. Following the transaction, the director now owns 1,251,900 shares of the company’s stock, valued at approximately $18,778,500. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.